Updates in Hepatopancreatobiliary Malignancy 2025: Metastatic Colorectal Cancer and Pancreas Cancer

The management of patients with hepatopancreatobiliary malignancies continues to evolve with the development of novel therapeutics and innovative surgical strategies. These scientific advances have transformed the management of patients with metastatic colorectal cancer and pancreas cancer, leading to improvements in survival and quality of life.

This two-part symposium, offered in-person only, will highlight recent advances in the management of colorectal liver metastases and provide a state-of-the-art update from the David M. Rubenstein Center for Pancreatic Cancer Research.

Part 1: Treatment of Colorectal Liver Metastases

The first part of this program will focus on innovations in the management of colorectal cancer metastases to the liver. Sessions will feature expert presentations and interactive discussions on novel therapeutics, emerging biomarkers, and evolving surgical strategies for both resectable and unresectable disease. Dynamic debates will further explore best practices for optimizing patient outcomes.

Part II: Updates in Pancreatic Cancer

The second part of the symposium will provide a state-of-the-art update from the David M. Rubenstein Center for Pancreatic Cancer Research (CPCR) at MSK, highlighting the latest discoveries and therapeutic advances in the management of pancreatic adenocarcinoma.

Networking Reception

A networking reception will follow Thursday’s program, providing an opportunity for faculty and participants to connect, exchange ideas, and foster new collaborations. If you would like to attend the networking reception, please indicate this when completing your registration.

Target Audience

This symposium is intended for medical and surgical oncologists, gastroenterologists, internal medicine specialists, pathologists, geneticists, pharmacists, supportive care staff, advanced practice practitioners, nurses, trainees, and other healthcare professionals. Patients and their families are also welcome to attend complimentary. Please see registration details below for more information.

1. Summarize the evolving role of liver resection for managing hepatic malignancy
2. Discuss the role of regional chemotherapy in the management of metastatic and primary liver cancer
3. Implement recent advances in pancreatic cancer research

This symposium is offered exclusively as an in-person event. Early discounted registration is available through October 9, 2025.

Early Registration Fees (before October 9, 2025)

• Physicians (MDs, PhDs, DOs): $300

• Advanced Practice Providers: $200

• Nurses: $125

• Residents, Fellows, Trainees: $125

• Industry Professionals*: N/A (general rates apply)

General Registration Fees (after October 9, 2025)

• Physicians (MDs, PhDs, DOs): $350

• Advanced Practice Providers: $250

• Nurses: $175

• Residents, Fellows, Trainees: $175

• Industry Professionals*: $625

Patients and Caregivers: Please complete our complimentary registration request here.

MSK Employees: Sign in to the MSK CME Portal using your SSO credentials for complimentary registration.

Registration Discounts: Discounted registration is available for specific groups. If eligible, you will receive further instructions and a promotion code to use during registration. View our Policy on Registration Discounts for more information.

Meals and Accommodations: Continental breakfast, lunch, and refreshment breaks will be provided to participants. If you have dietary restrictions or require special accommodations to attend in person, please contact us at [email protected] at least one week prior to the course.

Cancellation Policy: For details on our cancellation terms, please review our Cancellation Policy.

*An “industry professional” is defined as any individual—regardless of profession (e.g., MD, PhD, APP, RN)—who is employed by an ineligible company. View our Registration Policy for Industry Professionals for more information.

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The following continuing education credits will be offered:

• AMA PRA Category 1 Credits™

• ABIM Maintenance of Certification

• ABS Continuous Certification

• New York State Social Work Contact Hours (pending application approval)

• ANCC Nursing Contact Hours (pending application approval)

We look forward to welcoming you to Memorial Sloan Kettering Cancer Center (MSK).

If you’ll be traveling to New York City from out of town, we recommend that you plan your overnight stays as soon as possible. To make the planning a little easier, MSK has negotiated special rates and amenities at select hotels in Manhattan. Click here to view the list of select hotels and additional details on each.

For details on planning your visit to MSK, including travel and parking information, click here. Please note that parking validation is not available for attendees.

If you require any specific accommodations to attend this event in person, please contact [email protected] at least one week in advance.

MSK Symposium Directors

Enid A. Haupt Chair in Surgery
Director, Hepatopancreatobiliary Fellowship Program
Director, Surgical Oncology Fellowship Program
Vice Chair, Education
Attending, Hepatopancreatobiliary Service
Department of Surgery 

William R. Jarnagin, MD, FACS
Chief, Hepatobiliary Service
Leslie Blumgart Chair in Surgery
Department of Surgery 

Eileen M. O’Reilly, MD
Winthrop Rockefeller Endowed Chair of Medical Oncology
Chair, Human Research Protection Program and Institutional Review Board
Co-Director, Medical Initiatives, David M. Rubenstein Center for Pancreatic Cancer Research
Section Head, Hepatopancreaticobiliary and Neuroendocrine Cancers 
Attending, Member, Gastrointestinal Oncology Service
Department of Medicine 

Lily Victoria Saadat, MD
Assistant Attending, Hepatopancreatobiliary Service
Department of Surgery 

MSK Symposium Planning Committee 

Cristy Fitzpatrick, BSN, MA
Advanced Practice Provider 
Hepatopancreatobiliary Service

Mary Helen Larsen, MSN, RN, OCN®
Clinical Trials Nurse

David Hanna, MD
Fellow Planner

Mitigation of Relevant Financial Relationships

Memorial Sloan Kettering Cancer Center adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of the activity.